case_images: PMC5670294_01
case_images: Fourteen hours after initiation of terlipressin treatment skin purpuric lesions developed on the (A) left arm, (B) lower abdomen and (C, D) breasts
case_images: AnnGastroenterol-30-700-g001.jpg
case_images: PMC5670294_01_AnnGastroenterol-30-700-g001.jpg
case_images: F1
case_images: Two hours after the third 2 mg dose of terlipressin iv (doses given every 4 h), the patient developed purpuric skin lesions on her left arm (Fig. 1A), both breasts (Fig. 1C) and lower abdomen (Fig. 1B, D).
case_images: The evolution of skin lesions on the patient's left arm: (A) 24 h following initiation of terlipressin treatment; (B, C, D) 36 h following treatment initiation
case_images: AnnGastroenterol-30-700-g002.jpg
case_images: PMC5670294_01_AnnGastroenterol-30-700-g002.jpg
case_images: F2
case_images: The lesions evolved rapidly (Fig. 2) to necrosis and a cutaneous biopsy performed 48 h after the start of treatment led to the diagnosis of embolia cutis medicamentosa (ECM) or Nicolau syndrome (Fig. 3).